Vis enkel innførsel

dc.contributor.authorAass, Kristin Roseth
dc.contributor.authorTryggestad, Synne Stokke
dc.contributor.authorMjelle, Robin
dc.contributor.authorKastnes, Martin Haugrud
dc.contributor.authorNedal, Tonje Marie Vikene
dc.contributor.authorMisund, Kristine
dc.contributor.authorStandal, Therese
dc.date.accessioned2023-10-31T06:28:07Z
dc.date.available2023-10-31T06:28:07Z
dc.date.created2023-04-11T09:47:42Z
dc.date.issued2023
dc.identifier.citationFrontiers in Immunology. 2023, 14 .en_US
dc.identifier.issn1664-3224
dc.identifier.urihttps://hdl.handle.net/11250/3099541
dc.description.abstractMultiple myeloma (MM) is a hematological cancer characterized by accumulation of malignant plasma cells in the bone marrow. The patients are immune suppressed and suffer from recurrent and chronic infections. Interleukin-32 is a non-conventional, pro-inflammatory cytokine expressed in a subgroup of MM patients with a poor prognosis. IL-32 has also been shown to promote proliferation and survival of the cancer cells. Here we show that activation of toll-like receptors (TLRs) promotes expression of IL-32 in MM cells through NFκB activation. In patient-derived primary MM cells, IL-32 expression is positively associated with expression of TLRs. Furthermore, we found that several TLR genes are upregulated from diagnosis to relapse in individual patients, predominantly TLRs sensing bacterial components. Interestingly, upregulation of these TLRs coincides with an increase in IL-32. Taken together, these results support a role for IL-32 in microbial sensing in MM cells and suggest that infections can induce expression of this pro-tumorigenic cytokine in MM patients.en_US
dc.language.isoengen_US
dc.publisherFrontiersen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleIL-32 is induced by activation of toll-like receptors in multiple myeloma cellsen_US
dc.title.alternativeIL-32 is induced by activation of toll-like receptors in multiple myeloma cellsen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber0en_US
dc.source.volume14en_US
dc.source.journalFrontiers in Immunologyen_US
dc.identifier.doi10.3389/fimmu.2023.1107844
dc.identifier.cristin2139853
dc.relation.projectNorges forskningsråd: 223255en_US
dc.relation.projectSamarbeidsorganet mellom Helse Midt-Norge og NTNU: 90171600en_US
dc.relation.projectNorges forskningsråd: 274991en_US
dc.relation.projectSamarbeidsorganet mellom Helse Midt-Norge og NTNU: 90635300en_US
dc.relation.projectKreftforeningen: 198161en_US
dc.relation.projectSamarbeidsorganet mellom Helse Midt-Norge og NTNU: 30171600en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal